Showing Latest Articles
Estimating Health and Economic Benefits from Using Prescription Omega-3 Fatty Acids in Patients With Severe Hypertriglyceridemia
The American Journal of Cardiology, 08/29/2011
Samuel S et al. – P–OM3 medication is cost effective in this simulated trial and comparable to other cost–effective cardiovascular interventions.
Methods- Authors used the previously validated Archimedes model to simulate a 20–year trial involving subjects 45 to 75 years old with SHTG.
- The trial consisted of an intervention arm (P–OM3 4 g/day) and a control arm.
- Simulation results for the control arm indicated that subjects with SHTG are at about 2 times higher risk for myocardial infarction than those with normal triglyceride levels.
- Using estimates from previous epidemiologic studies and meta–analyses with OM3s, the model predicted 29% to 36% decreases in various measurements of adverse cardiac events for the intervention arm.
- The model also predicted a decrease in ischemic stroke of 24% (95% confidence interval 15 to 33).
- For the 20–year simulated trial, the cost per quality–adjusted life–year gained for the currently available P–OM3 approved by the Food and Drug Administration was $47,000.
- Results remained robust under different clinical assumptions.
- In this model P–OM3 was effective in decreasing triglyceride levels and cardiovascular disease risk in patients with SHTG.